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Background: The aims of this study were to assess the seroprevalence of vaccine-preventable infections in Emirati
medical students, and to provide scientific evidence for implementation of a cost-effective immunization guideline
and policy for medical school admission.
Methods: This prospective cohort study involved 261 (61% female) Emirati medical students (preclinical and
clinical) attending the College of Medicine and Health Sciences at UAE University. Data on vaccination and history
of infectious diseases were collected from participants. Blood samples were collected between July 1, 2011 and
May 30, 2012 for serological testing and QuantiFERONW-TB assay.
Results: All students tested negative for infection with hepatitis C virus and human immunodeficiency virus. The
prevalence of seropositivity to rubella virus was 97%, varicella–zoster virus 88%, mumps virus 84%, measles virus
54%, hepatitis B virus (HBV) 48%, and hepatitis A virus 21%. The QuantiFERONW-TB test was positive in 8% and
indeterminate in 2%. Forty percent of students received HBV vaccine at birth; their HBV titers (mean ± SD) were
17.2 ± 62.9 mIU/mL (median = 1.64). The remaining 60% received it at school and their titers were 293.4 ±
371.0 mIU/mL (median = 107.7, p = 0.000).
Conclusion: About 50% of students were susceptible to HBV and measles virus; therefore, pre-matriculation
screening for antibodies against these viruses is highly recommended. Moreover, tuberculosis screening is necessary
because of the high influx of expatriates from endemic areas. Students with inadequate protection should be
reimmunized prior to contact with patients.
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Immunity against vaccine-preventable and other transmis-
sible infections is of major importance, especially in medical
students who are at increased risk of exposure to infectious
body fluids [1]. Thus, pre-matriculation screening and
immunization policies are much needed for medical school
admission. Implementation of cost-effective programs,
however, requires surveillance that identifies immunization
gaps and susceptibility to infectious diseases.* Correspondence: msheekhussein@uaeu.ac.ae
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distribution, and reproduction in any mediumIn one study, about 50% of medical students reported
exposure to infectious body fluids and 0.3% reported a
needle stick injury [2]. Even higher incidences of exposure
to infectious body fluids were found in other studies [3,4].
One case report describes a student who contracted
encephalitis associated with measles [5]. A recent report
from Australia pointed out that many medical students
were not immune to vaccine-preventable infections, and
their self-reported history of previous vaccination was
often inaccurate [6].
The United Arab Emirates (UAE) was the first among the
Gulf Council Countries to adopt the WHO Expanded
Program on Immunization (EPI). As a result, childhood
vaccine-preventable diseases have almost been eliminated,Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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immunity against some of these infections weans off in
time and results in unsustainable protection in adults [8].
The aims of this study were to assess serological
immunity against vaccine-preventable and other trans-
missible infections in Emirati medical students, and to
provide scientific evidence for development of effective
pre-matriculation screening and immunization policies for
our students during the admission process.
Methods
Study participants and data collection
This prospective study involved a cohort of Emirati medical
students attending the College of Medicine and Health
Sciences at UAE University. Among 397 matriculated
students, 319 (80%) consented and enrolled in the study.
Between July 1, 2011 and May 30, 2012, blood was col-
lected from 261 (82%) students [158 (61%) female]. The
remaining 58 (18%) students had time conflicts with classes
and delayed the testing. The only exclusion criterion was
not consenting to the study. Details about age were only
available for 177 (68%) students: mean ± SD, 21.2 ± 2.3 years
of age; median, 21 years; range, 16–33 years of age.
Blood was collected from all 261 students for measuring
antibody titers against measles, mumps and rubella viruses,
varicella–zoster virus (VZV), hepatitis A virus (HAV),
hepatitis B virus (HBV), and hepatitis C virus (HCV).
Moreover, they were all requested to undergo human
immunodeficiency virus (HIV) antigen and antibody and
QuantiFERONW-TB Gold tests. Missing test values were
caused by various factors, including inadequate serum
volume to run all the tests, and a shortage of reagents or
analytical kits.
A brief self-administered questionnaire (provided by 319
students) was used to collect demographic data, which
included immunization and medical histories. Students
were also asked to bring their official immunization records
(provided by 91 students).
The study was approved by the institutional review
board for protection of human subjects (Assessment of
Immunization Status of Vaccine-Preventable Diseases for
Cohort Medical Students at College of Medicine and
Health Sciences, UAE University; reference number 10/59).
Informed consent was obtained from each participant.
Laboratory testing
Blood was collected for measuring antibody titers
against measles virus (VIDASW Measles IgG, REF 30
219; Biomerieux, Lyon, France); mumps virus
(VIDASW Mumps IgG, REF 30 218; Biomerieux); ru-
bella virus (Rubella IgG, REF 6C17, 840627/R3;
Abbott, Wiesbaden, Germany); VZV (VIDASW Varicella–
Zoster IgG, REF 30 217; Biomerieux); HAV (HAVAb-IgG,
REF 6C29, 36-6800/R1, B6C290; Abbott); HBV (Anti-HBs,REF 7C18, 48-8436/R7, B7C180; Abbott); and HCV (Anti-
HCV, REF 6C37, 48-6176/R6, B6C370; Abbott). HIV anti-
gen and antibody tests (HIV Ag/Ab Combo, REF 4 J27,
49-9527/R01, B4J2S0; Abbott) and QuantiFERONW-TB
Gold (In-Tube Method; Cellestis, Hannover, Germany)
were also performed. All tests were performed and all
results were interpreted according to manufacturers’
instructions.
Statistical analysis
The data were summarized by arithmetic mean and
standard deviation. Mann–Whitney U test was used for
nonparametric values; p < 0.05 was statistically significant.
Results
All tested students were nonreactive for HCV and HIV.
VZV serology was available in 182 (70%) of 261 students.
One hundred and sixty-one (88%) students were positive,
nine (5%) were equivocal, and 12 (7%) were negative
(Table 1 and Figure 1).
HBV serology was available in 181 (69%) of 261 students;
95 (52%) had a titer <10.0 mIU/mL (nonreactive) and 86
(48%) had a titer >10.0 mIU/mL (reactive) (Table 1 and
Figure 1). Of 136 students with a matched age and HBV
serology, 55 (40%) were <20 years of age and received
vaccination at birth, and had mean HBV titers of 17.2 ±
62.9 mIU/mL (median = 1.64). The remaining 81 (60%) stu-
dents were >20 years of age and received vaccination at
school, and had mean HBV titers of 293.4 ± 371.0 mIU/mL
(median = 107.7, p = 0.000). Of the 55 students who
received HBV vaccine at birth, 44 (80%) were nonreactive.
By contrast, of the 81 students who received HBV vaccine
at school, only 27 (33%) were nonreactive (p = 0.000). Fifty-
six students presented official records of HBV vaccination
at birth and had HBV titers of 62.1 ± 195.4 mIU/mL
(median = 1.8); 39 (70%) students were nonreactive and 17
(30%) were reactive. By contrast, 17 students presented
official records of HBV vaccination at school and had HBV
titers of 216.8 ± 263.7 mIU/mL (median = 4.2, p = 0.000);
nine (53%) students were nonreactive and eight (47%) were
reactive (Figure 2).
HAV serology was available in 168 (64%) of 261 students.
Thirty-six (21%) students were reactive and 132 (79%) were
nonreactive (Table 1 and Figure 1).
Rubella serology was available in 181 (69%) of 261
students. The cutoff for positive rubella titer was
10 IU/mL and equivocal titer >5 and <10 (Table 1
and Figure 1). Of the 181 students, 175 (96.5%) had
a rubella titer of >11 IU/mL (reactive); one (0.5%;
18-year-old female student) had a titer of 3 IU/mL
(nonreactive) and five (3%; three female and two
male) had a titer of 9 IU/mL (equivocal). Thus, all
students had some immunity to rubella, except for
one female student.
Table 1 Seroprevalence and result of QuantiFERONW-TB assay of the studied transmissible infections in Emirati medical
students
Results Rubella1 Measles2 Mumps3 HAV4 HBV5 HCV4 VZ6 HIV7 QuantiFERONW-TB7
Positive (%) 96.5 54 84 21 48 0 88 0 8
Equivocal (%) 3 18 10 - - - 5 - 2
Negative (%) 0.5 28 6 79 52 100 7 100 90
1A positive result is >10 IU/mL, equivocal 5.0 to 9.9 IU/mL, and negative 0.0 to 4.9 IU/mL. Results were available in 181 (69%) of 261 students.
2A positive result is >0.70 relative fluorescence value (RFV), equivocal >0.50 to <0.70 RFV, and negative <0.50 RFV. Results were available in 180 (69%) of 261
students.
3A positive result is >0.50 RFV, equivocal >0.35 to <0.50 RFV, and negative <0.35 RFV. Mumps serology was available in 170 (65%) of 261 students.
4A reactive test is >1.0 relative light unit (RLU) and nonreactive <1.0 RLU. Results were available in 168 (64%) of 261 students.
5A reactive test is >10.0 mIU/mL and nonreactive <10.0 mIU/mL. Results were available for 181(69%) of 261 students.
6A positive result is >0.90 RFV, equivocal 0.60 to <0.90 RFV, and negative <0.60 RFV. The titer was available in 182 (70%) of 261 students.
7Please refer to the manufactures’ brochures. Results were available only in 182 (70%) of 261 students. Equivocal test indicates indeterminate.
Positive tests for HAV, HBV, HCV and HIV indicate reactive and negative tests indicate non-reactive.
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students. Fifty (28%) students were negative/nonreactive, 33
(18%) were equivocal, and 97 (54%) were positive/reactive
(Table 1 and Figure 1). Student age did not significantly
influence measles seroprevalence; of 136 students with a
matched age and measles serology, 39 (29%) were sero-
negative, 18 (13%) were equivocal, and 78 (57%) were
reactive. By contrast, rubella titers for students with
nonreactive (or equivocal) measles were 41 ± 40 IU/mL
(n = 103) and with reactive measles 66 ± 57 IU/mL (n =
105; p = 0.000) (Figure 3).
Mumps serology was available in 170 (65%) of 261
students. Eleven (6%) students were nonreactive, 16 (10%)
were equivocal, and 143 (84%) were reactive (Table 1 and
Figure 1). The QuantiFERONW-TB test was available in
only 182 (70%) of 261 students. Fourteen (8%) students
were reactive, four (2%) were indeterminate, and 164 (90%)
were nonreactive (Figure 4). The age range of abnormal
QuantiFERONW-TB test was 19–25 years, which did notFigure 1 Seroprevalence of rubella, measles, mumps, HAV,
HBV, HCV, VZV, HIV and QuantiFERONW-TB in the Emirati
students.significantly differ from those with a negative test (Table 1
and Figure 1).Discussion
Although all students reported receiving childhood
immunization, the data here show that approxi-
mately 50% of the students tested were susceptible
to HBV and approximately 46% to measles (equivo-
cal plus negative). These results are consistent with
recent reports from Germany and Switzerland [1,8].
The students were offered reimmunization for these
diseases. Significantly, 8% of students had positive
and 2% had indeterminate QuantiFERON
W
-TB Gold
test for tuberculosis (TB). After excluding active TB
disease, these students were offered treatment of
latent disease with a standard regimen of isoniazid
and vitamin B6 for 9 months.
Medical students are often exposed to infectious
materials during their clinical rotations [1-3,9].Figure 2 Seroprevalence of HBV titer as a function of student
age.
Figure 3 Seroprevalence of measles as a function of rubella
titer.
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eases may predispose them, their patients and healthcare
workers to serious sequelae. Thus, it is important to iden-
tify susceptible students and implement effective reimmu-
nization policy during school admission. The findings here
show significant immunization gaps in medical students, es-
pecially for HBV and measles virus. Rubella and mumps
viruses and VZV, on the other hand, are reasonably covered.
According to a report in 1994 from the university of
Sydney, 22% of medical students had one or more needle
stick injuries in the previous 2 years [9]. In another survey,
14–30% of medical students reported a needle stick injury
[3]. Consequently, risk of exposure to HBV, HCV and HIV
is substantial [4]. In our study, 18 of the 261 (6.8%) students
reported needle stick injury.Figure 4 Summary of the results of QuantiFERONW-TB Gold test
for tuberculosis.The annual incidence of acute hepatitis in the United
Kingdom between 1985 and 1988 was 4 per 100,000 in
adult males and 2 per 100,000 in adult females, and it
was estimated to be 25 per 100,000 surgeons [10]. More
importantly, studies have shown protective efficacy (~90%)
of HBV and other vaccines in healthcare workers [11,12].
UAE has intermediate endemicity with hepatitis B surface
antigen (HBsAg) carrier rates of 2–5% [13]. HBV vaccine
was introduced in the UAE in October 1991; all infants
received three doses of vaccine (at 0, 2 and 6 months of
age). Moreover, all school students born before October
1991 were vaccinated with three doses of vaccine by the
year 2000 (Annual Reports, 1992 and 2002; Preventive
Medicine Department, Ministry of Health, UAE). There-
fore, it is expected that Emirati students <20 years of age
would have received the first dose of vaccine at birth,
while those aged >20 years would have been expected to
receive it at school. It has been reported that among
immunocompetent children who respond to the complete
primary three-dose vaccination series with anti-HBsAg
concentrations of >10 mIU/mL, 15–50% have low or
undetectable concentrations of anti-HBsAg at 5–15 years
after vaccination [14]. Adults were noted to have rapidly
decreasing anti-HBsAg titers within the first year after
primary vaccination; titers of <10 mIU/mL were observed
in 30–60% within 9–11 years after vaccination [14]. This
finding is consistent with the titers of <10 mIU/mL found
in 52% of the studied students (Table 1 and Figure 1).
Several studies have demonstrated excellent immune
memory (anamnestic response to vaccine challenge) in
those individuals and that acquisition of HBsAg is rare
despite low or undetectable antibody levels several years
after vaccination [15]. Therefore, a booster dose may not
be necessary in fully vaccinated healthy people. The
notion is not applicable to immunocompromised subjects,
such as those with HIV infection and renal failure [15].
Data on the seroprevalence of HAV in UAE are lacking.
The only available information comes from 1995–1996,
when 960 samples were examined and showed that 60% of
the population had antibodies against HAV by the age 17–
20 years (intermediate endemicity) [16]. Only 21% of the
studied students had anti-HAV antibodies (Table 1 and
Figure 1). This decline in the seroprevalence of HAV
probably reflects the changing socioeconomic conditions.
VZV vaccine has been available in the UAE for >10 years,
but it has just recently been introduced to the national
immunization program [17]. VZV is highly contagious
and immunity is often acquired from natural infection.
This explains the relatively high seropositive rate
among the studied students. The IgG seronegativity (or
equivocal) rate to VZV was 12% (Table 1 and Figure 1). In
2001, Uduman et al. reported that varicella seropositive
rates among Emirati citizens increased with age: <10 years,
45.8%; 11–20 years, 68.4%; 21–30 years, 89.5%; 31–40 years,
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adults may lead to serious complications. A study on vari-
cella infection among hospitalized adults in UAE reported a
mortality rate of 4.9% and a high rate of complications,
such as pneumonia (28.4%), skin infection (25.4%),
septicemia (10.7%), encephalitis/meningitis (8.8%), acute
respiratory distress syndrome (6.8%), renal failure
(2.9%), and hepatic failure (1.9%) [19]. Thus, vaccination
against varicella for susceptible medical students is
highly recommended.
In the UAE, vaccine against measles was introduced
in 1980 and the combined vaccine against measles,
mumps and rubella (MMR) in 1984–1985. The initial
immunization schedule included one dose of measles
vaccine at 9 months of age. In 1984, a second dose of
MMR was introduced at school entry. Since 1986, the
second dose of MMR vaccine was introduced at 15 months
of age; the second dose at school entry was then reserved
only for children who missed the dose at 15 months of age.
By the end of 2004, the dose of measles vaccine at 9 months
of age was omitted from the vaccination schedule; the first
dose of MMR vaccine moved from 15 to 12 months of age
and the second dose remained at school entry (Annual
Reports, 1992, 1998, 2002, 2004, and 2010; Preventive
Medicine Department, Ministry of Health, UAE). Thus,
typically, Emirati students are expected to have received
one dose of measles vaccine at 9 months and a second dose
at 15 months. The relatively low measles seroprevalence
probably reflects early vaccination against measles in the
study cohort.
UAE was among the first countries to adopt the WHO
EPI. Consequently, childhood vaccine-preventable diseases
have been almost eliminated, with an immunization
coverage reaching 98% (WHO/ Ministry of Health Annual
Report, 2010). The current challenges, however, are to
indentify immunization gaps in particularly susceptible
groups and implement reimmunization policies to
address the gaps. The data here show that 50% of
students tested were susceptible to HBV and measles
virus and require reimmunization. Furthermore, the
results prove that the QuantiFERONW-TB test should
be included in admission screening, especially in areas
where BCG vaccine use is universal.
The total number of measles cases reported nationally
(estimated population of about 5.4 million) between 2001
and 2010 was 539, averaging 54 cases per year. The total
number of rubella cases reported nationally between 1998
and 2010 was 788, averaging 61 cases per year. The number
of reported cases of mumps between 2001 and 2010,
however, was much larger, averaging 342 cases per year.
For 2010, the incidence rate (per 100,000) of VZV was
258.2 and 66.5 for all types of viral hepatitis.
Based on our findings, prematriculation screening tests
should at least include serology for HBV and measles virusand QuantiFERONW-TB testing. Students who are non-
reactive or equivocal for HBV and measles virus need
reimmunization. Students with a positive or indeterminate
QuantiFERONW-TB test need clinical assessment and
further work-up.
Conclusion
Significant numbers of students are susceptible to HBV
and measles; therefore, pre-matriculation screening for
antibodies against HBV and measles is recommended.
Serological studies in preclinical years are necessary to
ensure adequate protection before the students are in
close contacts with patients. The endeavor is needed even
in areas with reported high immunization coverage rates.
Interpretation of the recently introduced QuantiFERONW-
TB requires further evaluation, especially in regions of
indiscriminatory use of BCG at birth. Nevertheless, all
students with positive or indeterminate QuantiFERONW-
TB test require thorough clinical evaluation by infectious
disease consultants.
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